Effects of Isolated Limb Perfusion With Tumor Necrosis Factor-α on Circulating Levels of Proinflammatory Cytokines

Journal of Immunotherapy

Volumn 24, Issue 4, 2001, Pages 354-362

  Ferroni, Patrizia ^a   Di Filippo, Franco ^a   Martini, Francesca ^a   Spila, Antonella ^a   D'Alessandro, Roberta ^a   Cavaliere, Francesco ^a   Anzà, Michele ^b   Garinei, Rosa ^b   Aloe, Simona ^b   Carone, Maria Daniela ^b   Gazzaniga, Pier Paolo ^b   Guadagni, Fiorella ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cytokines; Isolated limb perfusion; Selectins; Systemic inflammatory response syndrome; TNF

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INFLAMMATION; INFLAMMATORY CELL; LIMB PERFUSION; MALE; MELANOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SARCOMA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; BLOOD COAGULATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CYTOKINES; EXTREMITIES; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; SARCOMA; SELECTINS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 17944380336     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200107000-00011     Document Type: Article

References (26)

1. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FS. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
2. Lejeune FS, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer 1993; 29A: 606-12.
3. Tracey KS, Bentler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
4. Wada H, Ohiwa M, Kaneko T, et al. Plasma levels of tumor necrosis factor in disseminated intravascular coagulation. Am J Hematol 1991; 37: 147-51.
5. Roberts DJ, Davies JM, Evans CC, Bell M, Mostafa SM, Lamche H. Tumor necrosis factor and adult respiratory distress syndrome. Lancet 1989; 2: 1043-4.
6. Simpson SQ, Casey LC. Role of tumor necrosis factor in sepsis and acute lung injury. Crit Care Clin 1989; 5: 27-47.
7. Strieter RM, Kunkel SL. Acute lung injury: the role of cytokines in the elicitation of neutrophils. J Investig Med 1994; 42: 640—51.
8. Quinn TD, Polk Jr, HC, Edwards MJ. Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines. Cancer Immunol Immunother 1995; 40: 272-5.
9. Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag PM. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med 2000; 28: 1040-6.
10. Stam TC, Swaak AJ, de Vries MR, ten Hagen TL, Eggermont AM. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000; 7: 268-75.
11. Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG, Swaak AJ. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 1998; 28: 520-7.
12. Swaak AJ, Lienard D, Schraffordt Koops H, Lejeune FJ, Eggermont AM. Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 1993; 23: 812-8.
13. Stam TC, Eggermont AM, Swaak AJ. Effects of tumour necrosis factor alpha and melphalan on the cytokine production of circulating T cells in patients with cancer. Eur J Clin Invest 1999; 29: 256-63.
14. Stam TC, Jongen-Lavrencic M, Eggermont AM, Swaak AJ. Effects of isolated limb perfusion with tumor necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer. Eur J Clin Invest 1996; 26: 1085-91.
15. Strieter RM, Kunkel SL. Acute lung injury: the role of cytokines in the elicitation of neutrophils. J Investig Med 1994; 42: 640-51.
16. Renard N, Liénard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 1994; 57: 656-63.
17. Renard N, Nooijen PT, Schalkwijk L, et al. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995; 176: 279-87.
18. Nooijen PT, Eggermont AM, Verbeek MM, et al. Transient induction of E-selectin expression after TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother 1996; 19: 33-44.
19. Di Filippo F, Calabrò A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with antiblastic perfusion. Cancer 1989; 63: 2551-61.
20. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conferences. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
21. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995; 13: 264-73.
22. Ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJH. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 1997; 78: 415-9.
23. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-9.
24. Salgado A, Boveda JL, Monasterio J, et al. Inflammatory mediators and their influence on haemostasis. Haemostasis 1994; 24: 132-8.
25. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-42.
26. Katsuyama I, Mayumi T, Kohanawa M, Ohta Y, Minagawa T, Kemmotsu O. Bleeding induced interleukin-6 decreases blood loss via activation of coagulation. Shock 1999; 11: 87-92.